Argenx
Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.
DitchCarbon Score
How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Argenx's score of 28 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Argenx's reported carbon emissions
In 2023, Argenx reported total carbon emissions of approximately 433,353,000 kg CO2e. This figure includes emissions across all three scopes: Scope 1 emissions totalled about 378,000 kg CO2e, while Scope 2 emissions were approximately 189,000 kg CO2e (market-based) and 183,000 kg CO2e (location-based). The majority of their emissions, approximately 432,786,000 kg CO2e, fall under Scope 3, which encompasses various categories such as purchased goods and services (about 378,956,000 kg CO2e), capital goods (approximately 28,054,000 kg CO2e), and business travel (around 5,328,000 kg CO2e). Currently, Argenx has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. However, the company is actively engaged in monitoring and reporting its emissions, which is a crucial step in addressing climate change. As a global biopharmaceutical company headquartered in the Netherlands, Argenx is positioned to contribute to industry-wide efforts in reducing greenhouse gas emissions and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 378,000 |
| Scope 2 | 189,000 |
| Scope 3 | 432,786,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
